Skip to main content
Søg
Menu
Luk menu
Danmark
  • da
  • en
  • Sweden
  • Norway
  • Finland
  • Nordic
  • Global
  • da
  • en
Danmark
  • Sweden
  • Norway
  • Finland
  • Nordic
  • Global
  • Medarbejdere
  • Sektorer

    Detail

    Energi og forsyning

    Fast ejendom

    Finansiel sektor

    Forsikring

    Forsvar og sikkerhed

    Hotel, restauration og fritid

    Industri

    Landbrug og fødevarer

    Life Sciences

    Medier, sport og entertainment

    DLA_Ikon_Hospitality_and_Leisure-02

    Minedrift

    Shipping, transport og logistik

    Teknologi

  • Fagområder

    Fagområder

    Corporate M&A

    Ansættelsesret

    Energi og infrastruktur

    Finans

    IP og teknologi

    International handel, regulatoriske og offentlige forhold

    Insolvens og rekonstruktion

    Retssager, voldgift & undersøgelser

    Fast ejendom

    Skatteret

  • Karriere
  • Nyheder
  • Om os
  • DLA Piper Insights: ESG
  • Events
  • Podcasts
  • Webinarer
  • Videoer
  • Publikationer
  • Kontakt
Tilmeld dig vores nyhedsbreve
Aktuelt
A pharmaceutical company was ordered to cease their advertising in its current form and fined DKK 50,000 plus VAT

A pharmaceutical company was ordered to cease their advertising in its current form and fined DKK 50,000 plus VAT

Ulrik Bangsbo Hansen
Ulrik Bangsbo Hansen
Partner
Head of Life Sciences, Denmark
Anette Moll Berg
Anette Moll Berg
Partner
nyhed
11 apr 2024
Faglig nyhed

On 31 January 2024, the Investigator’s Panel, appointed by the Danish Ethical Committee for the Pharmaceutical Industry (ENLI), found a company’s use of promotional material on an exhibition stand in violation of the Promotion Code (adopted by ENLI). The case arose after another company filed a complaint to ENLI. 

The case involved 3 different complaints considered by the Panel.

The first complaint concerned the requirements of the Promotion Code (adopted by ENLI) for information in advertising for medicinal products, Information about dosage, the delivery group, and the date of the latest revision of the material was not provided. Further it was not informed, as required, that the summary of product characteristics can be obtained free of charge from the marketing holder. Also, sections that did not use the specific wording of the summary of product characteristics or were abbreviated, were not highlighted as required. Several noteworthy elements were inappropriately omitted. This includes the premise of optimal underlying pharmacological and non-pharmacological treatment, among others. Finally, there was no reference to the current prices on medicinpriser.dk. Overall, the mandatory information was not easy to read.

The second complaint concerns the documentation of claims about medicines. The Panel assessed that several statements were not properly documented in the material. This is, for example, the statement "Prolastina, the most preferred choice among healthcare professionals". In addition, two of the statements violate the requirement for objectivity in the Advertising Code. Finally, the statement "Prolastina with more than 35 years of clinical experience" is documented by reference to data-on-file and market research that can be purchased. The requirement for documentation of indirect claims for medicinal products is not fulfilled by this type of documentation.

The third complaint concerns reference to mandatory texts, which in this case were on a roll-up. Such information must appear clear for the natural target audience of the advertisement to be able to read it easily. The statement on the roll-up was: "Full product information is available at the exhibition stand". The Panel found based on earlier practice that there is an exception to the main rule, but that it is strictly interpreted. This means that it is not enough to make the mandatory information available at a stand next to a roll-up, but that the compulsory text must be freely available and clearly indicated on the roll-up.

The Panel ruled in favor of the complainant in all three matters. The company was ordered to cease using the advertisement in its current form and was also fined DKK 50,000 + VAT.

The decision can be read here (in Danish only).

Download
Download som PDF
Sektorer
  • Life Sciences
Share

Relevante nyheder

DLA Piper Global M&A Intelligence Report 2025
nyhed

Global M&A Intelligence Report 2025

23 maj 2025
Faglig nyhed
nyhed

Sø- og Handelsrettens Dom om Kæntring af Flydedok

14 maj 2025
Sager
Alle nyheder
Nyhedsbrev

Tilmeld dig vores nyhedsbreve

Kunne du tænke dig at modtage nyhedsbreve og invitationer til seminarer mm. inden for juridiske områder, der er relevante for dig? Så tilmeld dig et eller flere af vores nyhedsbreve her.
Tilmeld dig her

Hvad kan vi gøre for dig?

Jeg er ikke en robot Læs mere
To prevent bots, crawlers and similar malicious digital agents to spam and misuse webforms, a special checkbox like this can help to block such agents.
© 2025 DLA Piper

DLA Piper Denmark Advokatpartnerselskab

Oslo Plads 2
2100 København Ø
Danmark

DOKK1 Hack Kampmanns Plads 2, Niveau 3
8000 Aarhus C
Danmark

(+45) 33 34 00 00
denmark@dk.dlapiper.com

CVR nr.
35 20 93 52

  • Om os
  • Nyheder
  • Events
  • Podcasts
  • Webinarer
  • Videoer
  • Publikationer
  • Kontakt
  • DLA Piper Global
  • Alumni
  • Cookie politik
  • CSR
  • Legal notices
  • Forretningsbetingelser
  • Presse
  • Privatlivspolitik
  • Oplysningspligt
  • Betalingsoplysninger
  • Kreditorportal
  • Slavery and Human Trafficking Statement
Group 3 Created with Sketch. Group 2 Created with Sketch.
Tilmeld dig vores nyhedsbreve

DLA Piper er en global advokatvirksomhed, der driver virksomhed gennem en række særskilte juridiske enheder. For yderligere oplysninger om disse enheder og DLA Pipers struktur henvises til siden Legal Notices på vores globale hjemmeside. Med forbehold for alle rettigheder. Advokatannoncering.

Nej tak
Nyhedsbrev

Tilmeld dig vores nyhedsbreve

Kunne du tænke dig at modtage nyhedsbreve og invitationer til seminarer mm. inden for juridiske områder, der er relevante for dig? Så tilmeld dig et eller flere af vores nyhedsbreve her.
Tilmeld dig her